Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China

Liang, Yongfeng; Wang, Xiaodong; Seyedmousavi, Seyedmojtaba; Yuan, Juan-Na; Abulize, Palida; Pan, Weihua; Yu, Nong; Yang, Yuchao; Hu, Haiqing; Liao, Wanqing; Deng, Shuwen

doi:10.1007/s11046-018-0305-2

Cited by 15 publications

(29 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, about half of C. albicans isolates (51.6%) tested were classified as exhibiting an intermediate susceptibility to voriconazole, whereas 25.8% and 13.5% of the isolates were resistant to fluconazole and voriconazole, respectively. Compared to our previous study in western China [5], fluconazole resistance of C. albicans isolates from VVC significantly increased in eastern China (8.2% resistance rate in western China versus 25.8% resistance rate in Suzhou, eastern China). Our results were also compatible with most Chinese reports indicating that approximately half of C. albicans isolates causing VVC were susceptible to fluconazole [21][22][23].…”

Section: Discussioncontrasting

confidence: 86%

“…Vulvovaginal candidiasis (VVC) is one of the most common vaginitis caused by Candida albicans, which accounts for 80-95% of all episodes of VVC worldwide, though the number of non-albicans species (such as Candida glabrata) as etiological agents of VVC is increasing [1,2]. An increasing prevalence of fungal resistance is also reported in antifungal surveillance studies globally [3][4][5]. Antifungal susceptibility testing of C. albicans isolates therefore plays a crucial role for appropriate and effective management strategies of VVC [5].…”

Section: Introductionmentioning

confidence: 99%

“…An increasing prevalence of fungal resistance is also reported in antifungal surveillance studies globally [3][4][5]. Antifungal susceptibility testing of C. albicans isolates therefore plays a crucial role for appropriate and effective management strategies of VVC [5]. In addition, it is important to look into the population genetic structure and epidemiology of C. albicans infections because of increasing reports indicating dynamic changes in the antifungal susceptibility profile with different genotypes and geographic origins [6].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Genotyping and Drug Resistance Profile of Clinical Isolates of Candida albicans from Vulvovaginal Candidiasis in the Eastern China

et al. 2022

Self Cite

View full text Add to dashboard Cite

A total of 244 Candida albicans isolates recovered from vulvovaginal candidiasis (VVC) patients in Suzhou, Eastern China, were investigated. According to CLSI documents M27-A4 and M59-3ed/M60-2ed, the MIC geometric means of nine antifungals in increasing order were micafungin (0.048 mg/L), anidulafungin (0.132 mg/L), caspofungin (0.19 mg/L), itraconazole (0.23 mg/L), posaconazole (0.25 mg/L), voriconazole (0.28 mg/L), 5-flucytosine (0.44 mg/L), amphotericin B (0.49 mg/L) and fluconazole (2.01 mg/L) respectively. Of note, 6.5% (16/244) C. albicans isolates showed resistance mainly to anidulafungin (mono-echinocandin resistance), while voriconazole had the lowest susceptibility rate of 34.8% (85/244), followed by fluconazole 59.4% (145/244), respectively. All isolates were genotyped by allelic combination of 3 microsatellite markers (CEF3, CAIII and LOC4). A total of 129 different allelic genotypes were identified, in which seven different clades were recognized with a discriminatory power of 0.96. Genotypes A-D were present in 35% of the isolates. In conclusion, decrease in antifungal drug susceptibility to C. albicans isolates from VVC is alarming. Our findings revealed the genetic diversity of C. albicans isolates among VVC patients and provided insights into the molecular epidemiology of Candida infections in China.

show abstract

Section: Discussioncontrasting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genotyping and Drug Resistance Profile of Clinical Isolates of Candida albicans from Vulvovaginal Candidiasis in the Eastern China

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The population of these 9 provinces accounts for one‐third of the country's population, and provides a very good representation of the infection status of vulvovaginal candidiasis in China. Liang Yan et al 30 held the view that ravuconazole showed good effectiveness against C. albicans isolated from VVC (MIC 50 and MIC 90 values were 0.063 and 1 µg/ml), which is higher than were reported in studies against Candida bloodstream isolates (MIC 50 and MIC 90 were 0.007 ~ 0.03 µg/ml and 0.016 ~ 0.125 µg/ml) 31,32 . In our study, MIC 50 (0.03 µg/ml) and MIC 90 (0.06 µg/ml) of ravuconazole against vaginal isolates appear to be more similar to the studies against the Candida bloodstream isolates.…”

Section: Discussionmentioning

confidence: 99%

“…24 Given that the treatment of VVC is still a difficult problem, the in vitro activities of most common and novel antifungal agents against vaginal Candida isolates have been investigated. [25][26][27][28][29] Furthermore, ravuconazole effectiveness against C. albicans isolated from vulvovaginal candidiasis in Xinjiang Province of China was observed in 2019, 30 but more information is needed to supplement our understanding.…”

Section: Discussionmentioning

confidence: 99%

In Vitro activity of ravuconazole against Candida auris and vaginal candida isolates

Dong

Liang

Zheng

et al. 2021

Mycoses

View full text Add to dashboard Cite

Background Ravuconazole is an extended‐spectrum triazole agent that is efficient in vitro against Candida spp. and has been approved to work as an oral formulae for onychomycosis in Japan in 2018. However, nobody had determined the MIC of ravuconazole against the Candida auris, which is known as an emerging multidrug‐resistant yeast. Meanwhile, rare is known of the in vitro activity of ravuconazole against vaginal Candida isolates. Objectives To investigate the activity of ravuconazole against C. auris and vaginal Candida isolates of China and assess the feasibility of ravuconazole in the treatment of candidiasis caused by C. auris and other Candida spp. Methods We determined the in vitro activity of ravuconazole and 9 comparators against 15 C. auris isolates and determined the MIC of ravuconazole on 525 vaginal Candida isolates (Candida albicans, Candida tropicalis, Candida glabrata and Candida parapsilosis) from 9 provinces of China by Clinical and Laboratory Standards Institute (CLSI) methodology. Results The MICs of fluconazole and amphotericin B on C. auris were much higher than second‐generation azoles and echinocandins. Ravuconazole was active against all the C. auris isolates and as effective as isavuconazole, posaconazole and echinocandins while showed a better antifungal activity than itraconazole, voriconazole to C. auris. For vaginal Candida isolates, the proportion of ravuconazole‐resistant isolates is 0.19% (1/525). Conclusions Ravuconazole was in good active against C. auris and vaginal Candida isolates, which suggested ravuconazole could be used in the treatment of drug‐resistant candidiasis.

show abstract

Inhibition of Phospholipase by Orlistat as an Alternate Therapy to Combat Opportunistic Mycosis Caused by C. albicans

et al. 2021

View full text Add to dashboard Cite

Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China

Cited by 15 publications

References 44 publications

Genotyping and Drug Resistance Profile of Clinical Isolates of Candida albicans from Vulvovaginal Candidiasis in the Eastern China

Genotyping and Drug Resistance Profile of Clinical Isolates of Candida albicans from Vulvovaginal Candidiasis in the Eastern China

In Vitro activity of ravuconazole against Candida auris and vaginal candida isolates

Inhibition of Phospholipase by Orlistat as an Alternate Therapy to Combat Opportunistic Mycosis Caused by C. albicans

Contact Info

Product

Resources

About